Deutsche Bank Upgrades Lam Research to Buy: 'Cyclical and Secular Tailwinds'
Deutsche Bank upgraded Lam Research to Buy, citing strong market trends including improved memory supply/demand and momentum at key foundries.
NOTRELOAD AI
Genmab's $8 Billion Move: Acquiring Merus to Lead the Next Wave of Cancer Antibody Therapeutics
Denmark's Genmab is acquiring Dutch drugmaker Merus for $8 billion to secure petosemtamab, a late-stage, breakthrough treatment for head and neck cancer, bolstering Genmab's proprietary oncology pipeline and accelerating its evolution into a global biotechnology leader.
Morgan Stanley Sees Downside to 2026-27 Consensus for Novo Amid Competition and Patent Risks
Novo Nordisk was downgraded because key drug sales (Ozempic/Wegovy) are slowing. Competition and future patent loss are hurting the stock.
MoonLake's Sonelokimab Trial Results for Hidradenitis Suppurativa: What Happened?
MoonLake announced Phase 3 results for sonelokimab (VELA trials) in HS. While one trial succeeded using the primary analysis, the other faced challenges due to a high placebo response, leading to a stock downgrade.
Occidental Petroleum Divests OxyChem to Reduce Debt
Buffett-backed Occidental Petroleum is preparing its largest-ever asset sale, aiming to sell its massive OxyChem division for an estimated $10 billion. This move is critical to help the company reduce its heavy debt burden.
Electronic Arts Nearing Potential Record $50 Billion Leveraged Buyout
Videogame giant Electronic Arts is nearing a deal to go private in what could become the largest leveraged buyout (LBO) in history, valued at up to $50 billion and backed by investors including Silver Lake and Saudi Arabia's Public Investment Fund.